E

89bio
D

ETNB

14.785
USD
-0.03
(-0.17%)
مفتوح الان
حجم التداول
16,109
الربح لكل سهم
-2
العائد الربحي
-
P/E
-4
حجم السوق
2,195,460,548
الأخبار المقالات

العنوان: 89bio

القطاع: Healthcare
الصناعة: Biotechnology
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).